Portfolio

Achillon Achillion Pharmaceuticals (NASD: ACHN), located in New Haven, Connecticut, is a biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for infectious diseases. The Company’s discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is currently developing treatments for HIV infection, chronic hepatitis C infection and serious hospital- based bacterial infections. Achillon completed its initial public offering in October 2006.

 


cardio focus CardioFocus, based in Maynard, Massachusetts, is developing, manufacturing and marketing proprietary, disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias such as atrial fibrillation. The CardioFocus catheter promises rapid, effective and permanent isolation of the pulmonary veins while overcoming the difficulties inherent in the current RF ablation procedures. Guided via integrated endoscopic visualization, the catheter helps physicians to accomplish ablation by projecting a series of overlapping arcs of both visible and infrared laser light upon the atrial wall surrounding each vein. Complete isolation is generally obtained with several 60-second energy deliveries – promising a great advantage in speed and precision in comparison to the large number of ablations required in current RF ablation procedures.

 


magellan Magellan, based in Chelmsford, MA, serves the worldwide clinical-diagnostics market with rapid point-of-care analyzers and automated systems for hospital-based labs and near-patient testing. Scientists use our discovery systems and sensors for cutting-edge research to develop a new understanding of health and illness — from disease pathology to biomarker identification. We design all of our systems, sensors, and consumables to deliver better, more-reliable results. And better results help drive improved health outcomes: earlier, more-accurate diagnoses; breakthroughs that can lead to novel treatments, new cures — innovations to enhance life. A privately held company, Magellan serves customers through wholly owned subsidiaries: ESA Biosciences, Dynex Technologies, and TekCel.

 


neuronetics Neuronetics, based in Malvern, PA, is an emerging medical device company focused on successfully developing and commercializing innovative, non-invasive therapies to treat psychiatric and neurological disorders using a technology called transcranial magnetic stimulation (TMS). TMS involves the use of very short pulses of magnetic energy to stimulate nerve cells in the brain. Neuronetics’ advanced TMS technology has completed investigation for the treatment of major depression in a series of integrated clinical trials. These trials evaluated its safety and ability to improve mood in major depression patients. Information from these trials will be submitted to the US Food and Drug Administration (FDA) to support clearance, which would ultimately allow US physicians to use Neuronetics’ technology to treat patients with symptoms of depression.

 


pneumrx PneumRx, based in Mountain View, CA, develops minimally invasive medical devices for interventional pulmonary and thoracic surgery. The company is initially focused on devices and related technologies for chronic obstructive pulmonary disease and lung cancer. PneumRx received 510(k) notification from the FDA in November 2005 for its family of biopsy needles and kits.

 


prolong Based in South Plainfield, New Jersey, Prolong Pharmaceuticals is developing products targeting the treatment of anemia resulting from an oxygen deficiency. The company’s clinical development efforts are focused on sickle cell anemia, diabetic ischemia, and several trauma indications. Prolong is also advancing a long-acting 3rd generation biologic for treating anemia associated with chronic kidney disease and cancer treatment. Originally established in 2002 as a research lab, in 2010, Prolong has emerged as a mature privately held biotech company. Led by a team of successful pharmaceutical executives, Prolong has multiple clinical development programs and large scale cGMP manufacturing facilities in production.

 


KBL Healthcare Ventures
52 East 72nd Street – PH
New York, NY 10021
Ph: (212) 319-5555
Fax: (212) 319-5591
Inquiries: admin@kblvc.com